RegeneRx Biopharmaceuticals, Inc.

3 Bethesda Metro Center, Suite 630
Bethesda
Maryland
20814
United States

Tel: 301-280-1992
Fax: 301-280-1996

Email: info@regenerx.com

Show jobs for this employer

302 articles with RegeneRx Biopharmaceuticals, Inc.

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the estimated timing of the statistical and regulatory plan for its phase 3 dry eye clinical trial (ARISE-3)

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)  ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial database evaluating RGN-259

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors in the market regarding its ARISE-3 phase 3 dry eye trial. 

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, issued a year-end Letter to Stockholders.  The Letter may be viewed

  • RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up.

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that its joint venture, ReGenTree LLC, has enrolled the last of 700 subjects in the ARISE-3 phase 3 clinical trial for dry eye syndrome.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a $500,000 convertible debt financing.  The funds will be used for operations while awaiting completion of its phas

  •  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that enrollment in the 700-patient, phase 3 clinical trial for dry eye syndrome (ARISE-3) is expected to be completed in November, 2020, and that th

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that it has verbally agreed to a short-term financing transaction with one of its major stockholders, and members of its board of directors and management. The f

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that a multi-institutional team of scientists from eight American research centers published  a  research paper on new therapeutic approaches for COVID-19 in which they propose that Thymosin beta 4 (Tβ4)

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that its U.S. joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the status of patient enrollment in its phase 3 dry eye clinical trial (ARISE-3). http://www.regenerx.com/2020-08-19-August-1

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the revised schedule for completion of the ARISE-3 dry eye clinical trial, http://www.regenerx.com/2020-06-02-June-2-2020-Advi

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the FDA's reclassification of Thymosin beta 4 (Tβ4) from a drug to a biologic,

  • RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration announced efficacy results of its Phase 3 clinical trial in patients with neurotrophic keratopathy.

  • ReGenTree, LLC, a U.S. joint venture company owned by GtreeBNT Co., Ltd, and RegeneRx Biopharmaceuticals, Inc., announced the results of a randomized, double masked, placebo-controlled Phase 3 clinical trial using RGN-259 for the treatment of neurotrophic keratopathy.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial.  To access the advisory, go to the following link:  http://www.regenerx.com/2020-04-20-Ap

  • RegeneRx Biopharmaceuticals, Inc. announced the publication of a new scientific study demonstrating a mechanism of action of thymosin beta 4 on human corneal epithelial cell migration and the downstream signaling pathways.

  • RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial.  To access the advisory, go to the following link:  http://www.regenerx.com/2020-03-18-Ma